Skip to main content

Abstract

Objective:

Functional neurological disorder (FND) is a core neuropsychiatric condition that includes both physical and mental symptoms. Recently, a validated clinical phenotype termed neuroconnective endophenotype (NEP), which includes several physical and psychological characteristics together with joint hypermobility (hypermobility spectrum disorders), was found at a significantly higher frequency among patients with anxiety. The purpose of the present study was to examine the presence of the NEP among patients with FND.

Methods:

The authors conducted a multicenter case-control study comprising 27 FND patients and 27 healthy control participants (matched by sex and age) ages 13 to 58 years. Eight questionnaires were administered. Proportional differences were examined with Student’s t tests, one-way analyses of variance, and chi-square tests.

Results:

Differences between FND patients and control participants were observed. FND patients had higher sensory sensitivity, increased prevalence of hypermobility features (including relevant physical signs and symptoms), greater frequency of polarized behaviors, a greater number of both psychiatric and physical comorbidities, and an increase in the characteristics and sensations typical of anxiety. Particularly striking was the presence of the hypermobility spectrum in more than 75% of FND patients compared with 15% among control participants.

Conclusions:

FND patients presented higher scores in all five dimensions included in the NEP. Thus, this phenotype, solidifying the original association between anxiety and the hypermobility spectrum, could help to identify an FND subtype when evaluating and managing FND patients, because it provides a new global view of patients’ physical and mental symptoms.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
PubMed: 39385576

History

Received: 18 January 2024
Revision received: 16 April 2024
Revision received: 25 April 2024
Revision received: 6 May 2024
Accepted: 6 May 2024
Published online: 10 October 2024

Keywords

  1. Anxiety Disorders
  2. Conversion Disorders
  3. Functional Neurological Disorder
  4. Hypermobility Spectrum Disorders
  5. Joint Hypermobility
  6. Neuroconnective Endophenotype

Authors

Details

Antonio Bulbena-Vilarrasa, M.D., Ph.D. [email protected]
Mental Health Institute, Hospital del Mar, Barcelona, Spain (Bulbena-Vilarrasa, Martínez-García, Pérez-Sola); Doctorate Program, Psychiatry and Forensic Medicine Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain (Bulbena-Vilarrasa, Martínez-García); Centro de Investigación Biomédica en Red de Salud Mental, Instituto de Salud Carlos III-ES, Madrid (Bulbena-Vilarrasa, Pintor Pérez, Pérez-Sola); Consultation Liaison Psychiatry Unit, Department of Psychiatry and Psychology, Hospital Clinic de Barcelona, Institute of Neuroscience Barcelona, Barcelona, Spain (Pintor Pérez, Camara, Arbelo-Cabrera); Department of Medicine, School of Medicine Barcelona, University of Barcelona, Barcelona, Spain (Pintor Pérez); August Pi i Sunyer Institute of Biomedical Research Barcelona, Catalunya, Spain (Pintor Pérez); Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York (Bulbena-Cabré); Facultad de Ciencias de la Salud y de la Vida, Universitat Pompeu Fabra, Barcelona, Spain (Pérez-Sola); Laboratoire de Psychopathologie et Processus de Santé, Université Paris Cite, Paris, Île-de-France, France (Baeza-Velasco); Department of Emergency Psychiatry and Acute Care, Montpellier 2 University, Montpellier, Occitanie, France (Baeza-Velasco); University of Montpellier, Centre National de la Recherche Scientifique, Inserm, Institute of Functional Genomics, Montpellier, Occitanie, France (Baeza-Velasco).
Maria Martínez-García, M.D., Ph.D.
Mental Health Institute, Hospital del Mar, Barcelona, Spain (Bulbena-Vilarrasa, Martínez-García, Pérez-Sola); Doctorate Program, Psychiatry and Forensic Medicine Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain (Bulbena-Vilarrasa, Martínez-García); Centro de Investigación Biomédica en Red de Salud Mental, Instituto de Salud Carlos III-ES, Madrid (Bulbena-Vilarrasa, Pintor Pérez, Pérez-Sola); Consultation Liaison Psychiatry Unit, Department of Psychiatry and Psychology, Hospital Clinic de Barcelona, Institute of Neuroscience Barcelona, Barcelona, Spain (Pintor Pérez, Camara, Arbelo-Cabrera); Department of Medicine, School of Medicine Barcelona, University of Barcelona, Barcelona, Spain (Pintor Pérez); August Pi i Sunyer Institute of Biomedical Research Barcelona, Catalunya, Spain (Pintor Pérez); Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York (Bulbena-Cabré); Facultad de Ciencias de la Salud y de la Vida, Universitat Pompeu Fabra, Barcelona, Spain (Pérez-Sola); Laboratoire de Psychopathologie et Processus de Santé, Université Paris Cite, Paris, Île-de-France, France (Baeza-Velasco); Department of Emergency Psychiatry and Acute Care, Montpellier 2 University, Montpellier, Occitanie, France (Baeza-Velasco); University of Montpellier, Centre National de la Recherche Scientifique, Inserm, Institute of Functional Genomics, Montpellier, Occitanie, France (Baeza-Velasco).
Luis Pintor Pérez, M.D., Ph.D.
Mental Health Institute, Hospital del Mar, Barcelona, Spain (Bulbena-Vilarrasa, Martínez-García, Pérez-Sola); Doctorate Program, Psychiatry and Forensic Medicine Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain (Bulbena-Vilarrasa, Martínez-García); Centro de Investigación Biomédica en Red de Salud Mental, Instituto de Salud Carlos III-ES, Madrid (Bulbena-Vilarrasa, Pintor Pérez, Pérez-Sola); Consultation Liaison Psychiatry Unit, Department of Psychiatry and Psychology, Hospital Clinic de Barcelona, Institute of Neuroscience Barcelona, Barcelona, Spain (Pintor Pérez, Camara, Arbelo-Cabrera); Department of Medicine, School of Medicine Barcelona, University of Barcelona, Barcelona, Spain (Pintor Pérez); August Pi i Sunyer Institute of Biomedical Research Barcelona, Catalunya, Spain (Pintor Pérez); Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York (Bulbena-Cabré); Facultad de Ciencias de la Salud y de la Vida, Universitat Pompeu Fabra, Barcelona, Spain (Pérez-Sola); Laboratoire de Psychopathologie et Processus de Santé, Université Paris Cite, Paris, Île-de-France, France (Baeza-Velasco); Department of Emergency Psychiatry and Acute Care, Montpellier 2 University, Montpellier, Occitanie, France (Baeza-Velasco); University of Montpellier, Centre National de la Recherche Scientifique, Inserm, Institute of Functional Genomics, Montpellier, Occitanie, France (Baeza-Velasco).
Mercé Camara, M.D.
Mental Health Institute, Hospital del Mar, Barcelona, Spain (Bulbena-Vilarrasa, Martínez-García, Pérez-Sola); Doctorate Program, Psychiatry and Forensic Medicine Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain (Bulbena-Vilarrasa, Martínez-García); Centro de Investigación Biomédica en Red de Salud Mental, Instituto de Salud Carlos III-ES, Madrid (Bulbena-Vilarrasa, Pintor Pérez, Pérez-Sola); Consultation Liaison Psychiatry Unit, Department of Psychiatry and Psychology, Hospital Clinic de Barcelona, Institute of Neuroscience Barcelona, Barcelona, Spain (Pintor Pérez, Camara, Arbelo-Cabrera); Department of Medicine, School of Medicine Barcelona, University of Barcelona, Barcelona, Spain (Pintor Pérez); August Pi i Sunyer Institute of Biomedical Research Barcelona, Catalunya, Spain (Pintor Pérez); Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York (Bulbena-Cabré); Facultad de Ciencias de la Salud y de la Vida, Universitat Pompeu Fabra, Barcelona, Spain (Pérez-Sola); Laboratoire de Psychopathologie et Processus de Santé, Université Paris Cite, Paris, Île-de-France, France (Baeza-Velasco); Department of Emergency Psychiatry and Acute Care, Montpellier 2 University, Montpellier, Occitanie, France (Baeza-Velasco); University of Montpellier, Centre National de la Recherche Scientifique, Inserm, Institute of Functional Genomics, Montpellier, Occitanie, France (Baeza-Velasco).
Néstor Arbelo-Cabrera, M.D.
Mental Health Institute, Hospital del Mar, Barcelona, Spain (Bulbena-Vilarrasa, Martínez-García, Pérez-Sola); Doctorate Program, Psychiatry and Forensic Medicine Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain (Bulbena-Vilarrasa, Martínez-García); Centro de Investigación Biomédica en Red de Salud Mental, Instituto de Salud Carlos III-ES, Madrid (Bulbena-Vilarrasa, Pintor Pérez, Pérez-Sola); Consultation Liaison Psychiatry Unit, Department of Psychiatry and Psychology, Hospital Clinic de Barcelona, Institute of Neuroscience Barcelona, Barcelona, Spain (Pintor Pérez, Camara, Arbelo-Cabrera); Department of Medicine, School of Medicine Barcelona, University of Barcelona, Barcelona, Spain (Pintor Pérez); August Pi i Sunyer Institute of Biomedical Research Barcelona, Catalunya, Spain (Pintor Pérez); Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York (Bulbena-Cabré); Facultad de Ciencias de la Salud y de la Vida, Universitat Pompeu Fabra, Barcelona, Spain (Pérez-Sola); Laboratoire de Psychopathologie et Processus de Santé, Université Paris Cite, Paris, Île-de-France, France (Baeza-Velasco); Department of Emergency Psychiatry and Acute Care, Montpellier 2 University, Montpellier, Occitanie, France (Baeza-Velasco); University of Montpellier, Centre National de la Recherche Scientifique, Inserm, Institute of Functional Genomics, Montpellier, Occitanie, France (Baeza-Velasco).
Andrea Bulbena-Cabré, M.D., Ph.D.
Mental Health Institute, Hospital del Mar, Barcelona, Spain (Bulbena-Vilarrasa, Martínez-García, Pérez-Sola); Doctorate Program, Psychiatry and Forensic Medicine Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain (Bulbena-Vilarrasa, Martínez-García); Centro de Investigación Biomédica en Red de Salud Mental, Instituto de Salud Carlos III-ES, Madrid (Bulbena-Vilarrasa, Pintor Pérez, Pérez-Sola); Consultation Liaison Psychiatry Unit, Department of Psychiatry and Psychology, Hospital Clinic de Barcelona, Institute of Neuroscience Barcelona, Barcelona, Spain (Pintor Pérez, Camara, Arbelo-Cabrera); Department of Medicine, School of Medicine Barcelona, University of Barcelona, Barcelona, Spain (Pintor Pérez); August Pi i Sunyer Institute of Biomedical Research Barcelona, Catalunya, Spain (Pintor Pérez); Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York (Bulbena-Cabré); Facultad de Ciencias de la Salud y de la Vida, Universitat Pompeu Fabra, Barcelona, Spain (Pérez-Sola); Laboratoire de Psychopathologie et Processus de Santé, Université Paris Cite, Paris, Île-de-France, France (Baeza-Velasco); Department of Emergency Psychiatry and Acute Care, Montpellier 2 University, Montpellier, Occitanie, France (Baeza-Velasco); University of Montpellier, Centre National de la Recherche Scientifique, Inserm, Institute of Functional Genomics, Montpellier, Occitanie, France (Baeza-Velasco).
Victor Pérez-Sola, M.D., Ph.D.
Mental Health Institute, Hospital del Mar, Barcelona, Spain (Bulbena-Vilarrasa, Martínez-García, Pérez-Sola); Doctorate Program, Psychiatry and Forensic Medicine Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain (Bulbena-Vilarrasa, Martínez-García); Centro de Investigación Biomédica en Red de Salud Mental, Instituto de Salud Carlos III-ES, Madrid (Bulbena-Vilarrasa, Pintor Pérez, Pérez-Sola); Consultation Liaison Psychiatry Unit, Department of Psychiatry and Psychology, Hospital Clinic de Barcelona, Institute of Neuroscience Barcelona, Barcelona, Spain (Pintor Pérez, Camara, Arbelo-Cabrera); Department of Medicine, School of Medicine Barcelona, University of Barcelona, Barcelona, Spain (Pintor Pérez); August Pi i Sunyer Institute of Biomedical Research Barcelona, Catalunya, Spain (Pintor Pérez); Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York (Bulbena-Cabré); Facultad de Ciencias de la Salud y de la Vida, Universitat Pompeu Fabra, Barcelona, Spain (Pérez-Sola); Laboratoire de Psychopathologie et Processus de Santé, Université Paris Cite, Paris, Île-de-France, France (Baeza-Velasco); Department of Emergency Psychiatry and Acute Care, Montpellier 2 University, Montpellier, Occitanie, France (Baeza-Velasco); University of Montpellier, Centre National de la Recherche Scientifique, Inserm, Institute of Functional Genomics, Montpellier, Occitanie, France (Baeza-Velasco).
Carolina Baeza-Velasco, Ph.D.
Mental Health Institute, Hospital del Mar, Barcelona, Spain (Bulbena-Vilarrasa, Martínez-García, Pérez-Sola); Doctorate Program, Psychiatry and Forensic Medicine Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain (Bulbena-Vilarrasa, Martínez-García); Centro de Investigación Biomédica en Red de Salud Mental, Instituto de Salud Carlos III-ES, Madrid (Bulbena-Vilarrasa, Pintor Pérez, Pérez-Sola); Consultation Liaison Psychiatry Unit, Department of Psychiatry and Psychology, Hospital Clinic de Barcelona, Institute of Neuroscience Barcelona, Barcelona, Spain (Pintor Pérez, Camara, Arbelo-Cabrera); Department of Medicine, School of Medicine Barcelona, University of Barcelona, Barcelona, Spain (Pintor Pérez); August Pi i Sunyer Institute of Biomedical Research Barcelona, Catalunya, Spain (Pintor Pérez); Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York (Bulbena-Cabré); Facultad de Ciencias de la Salud y de la Vida, Universitat Pompeu Fabra, Barcelona, Spain (Pérez-Sola); Laboratoire de Psychopathologie et Processus de Santé, Université Paris Cite, Paris, Île-de-France, France (Baeza-Velasco); Department of Emergency Psychiatry and Acute Care, Montpellier 2 University, Montpellier, Occitanie, France (Baeza-Velasco); University of Montpellier, Centre National de la Recherche Scientifique, Inserm, Institute of Functional Genomics, Montpellier, Occitanie, France (Baeza-Velasco).

Notes

Send correspondence to Dr. Bulbena-Vilarrasa ([email protected]).

Competing Interests

Dr. Pérez-Sola has served as a consultant to or received honoraria or grants from AB-Biotics, AstraZeneca, Bristol-Myers Squibb, Centro de Investigación Biomédica en Red de Salud Mental, FIS-ISCiii, Janssen Cilag, Lundbeck, Otsuka, Servier, and Medtronic. The other authors report no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

View options

PDF/EPUB

View PDF/EPUB

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Share article link

Share